Myriad Genetics GeneSight PGx Test Garners United Healthcare Coverage

UnitedHealthcare has issued a positive coverage decision for Myriad Genetics’ GeneSight Psychotropic pharmacogenetic test. The GeneSight test gauges variants associated with drug response and uses a color-coding system to provide information about which drugs patients are likely to respond to best based on their genetic makeup. In a coverage policy slated to take effect on Oct. 1, UHC said that pharmacogenetic multi-gene panels are medically necessary for guiding use of antidepressants and antipsychotic drugs for patients with major depressive disorder or anxiety, who have failed to respond to one or more treatments, and the multi-gene pane has no more than 15 relevant genes.

Source: https://www.genomeweb.com/business-news/myriad-genetics-genesight-pgx-test-garners-unitedhealthcare-coverage